The present study is the first comprehensive SLR focused on the global reported prevalence of FLT3 mutations among AML patients and features a robust compilation of over 50,000 patients with FLT3‐mutated AML, considerably larger than the largest previous study, which was a registry study of approximately 3500 patients (and has been included in this SLR) [49]. This evidence concerns the gene FLT3 and acute myeloid leukemia.